In a report released today, Raju Prasad from William Blair maintained a Buy rating on Poseida Therapeutics (PSTX). The company’s shares closed last Tuesday at $8.50, close to its 52-week low of $7.63.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 10.2% and a 46.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Poseida Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $30.00.
See today’s analyst top recommended stocks >>
Based on Poseida Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $36.15 million. In comparison, last year the company had a GAAP net loss of $23.61 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PSTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
